Statements (52)
Predicate | Object |
---|---|
gptkbp:instanceOf |
biotechnology company
|
gptkbp:businessModel |
research and development
biotech startup partnerships with pharma |
gptkbp:CEO |
Steve_Harr
|
gptkbp:clinicalTrials |
ongoing
Phase 1 data-driven decisions rare diseases Phase 2 Phase 3 innovative therapies patient-centric approach |
gptkbp:collaborations |
academic institutions
research organizations biopharmaceutical companies |
gptkbp:employees |
50-100
|
gptkbp:focus |
gene therapy
|
gptkbp:founded |
2018
|
gptkbp:founder |
Steve_Harr
|
gptkbp:funding |
gptkb:National_Institutes_of_Health
grants venture capital private investors |
gptkbp:headquarters |
gptkb:San_Francisco,_California
|
https://www.w3.org/2000/01/rdf-schema#label |
Sana Therapeutics
|
gptkbp:investmentFocus |
$100 million
|
gptkbp:is_aimed_at |
neurological disorders
muscle disorders |
gptkbp:leadership |
scientific advisory board
|
gptkbp:mission |
transform lives through gene therapy
|
gptkbp:partnerships |
gptkb:Duke_University
gptkb:University_of_California,_San_Francisco |
gptkbp:products |
therapeutics for rare diseases
therapeutics for genetic disorders therapeutics for inherited diseases |
gptkbp:regulatoryCompliance |
FDA_approved
|
gptkbp:research |
therapeutic development
|
gptkbp:research_areas |
gptkb:Duchenne_muscular_dystrophy
amyotrophic lateral sclerosis muscular dystrophy cellular therapies spinal muscular atrophy genetic medicine myotonic dystrophy |
gptkbp:technology |
CRISPR technology
AAV gene delivery |
gptkbp:tributaryOf |
multiple candidates
|
gptkbp:vision |
improving patient outcomes
leading gene therapy company advancing genetic medicine |
gptkbp:website |
www.sanatherapeutics.com
|